Autism Spectrum Disorder stems from alterations in neuronal connectivity and immune signalling during neurodevelopment.
Autism Spectrum Disorder stems from alterations in neuronal connectivity and immune signalling during neurodevelopment. Stem-cell research explores whether mesenchymal stem cells derived from placental tissue or amniotic membrane can modulate neuroinflammation, support synaptic plasticity, and promote neural integration. These cells are selected because they secrete immunoregulatory factors and can differentiate into supportive glial cells. Neurogenic cells are also being studied to repair damaged neural circuits, while exosomes — extracellular vesicles released by stem cells — are examined as vehicles for delivering anti-inflammatory signals to the brain. Current approaches remain investigational; the evidence base comprises preclinical work and early clinical trials. No mechanism yet explains why or how stem cells would alter the core neurobiological features of autism in humans.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €6,440–€92,000 (autism-mmc.com, cellmedicine.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Neurogenic Cells, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 26 · 6 recruiting now |
For the clinic's own description, see how Stem Plus describes its Autism Spectrum Disorder programme ↗.
Twenty-six registered trials and 6 actively recruiting studies explore stem-cell approaches in autism, primarily small, uncontrolled observational designs. Published reports describe behavioural changes in individual cases, but lack placebo controls, randomisation, or blinded assessment. Most data come from Asia-Pacific clinics; few reach peer-reviewed journals. The theoretical rationale — that placental MSCs reduce neuroinflammation — remains unproven in human brains. No trial has demonstrated meaningful, durable change in core autism features attributable to stem cells alone.
Depending on assessment, a Autism Spectrum Disorder protocol may draw on:
Indicative European costs run roughly €3,500–€7,500 per course, reflecting cell sourcing, delivery method (intravenous, intrathecal, or intranasal), and number of doses. Autism protocols often involve multiple infusions over weeks, increasing the total. Diagnostic workup, imaging, and post-infusion monitoring add further expense. The figure is indicative only and varies by clinic and protocol.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Autism Spectrum Disorder cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Autism Spectrum Disorder.
Full Autism Spectrum Disorder FAQ → · Autism Spectrum Disorder cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita